Search results
Results from the WOW.Com Content Network
The former Brussels Stock Exchange building. The BEL 20 is the benchmark stock market index of Euronext Brussels. It tracks the performance of 20 most capitalized and liquid stocks traded in Belgium. In general, the index consists of a minimum of 10 and a maximum of 20 companies traded at the Brussels Stock Exchange.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
The drugmaker now expects 2024 product revenue in the range of $10.65 to $10.85 billion, compared to its prior forecast of $10.55 to $10.75 billion. The company said that the forecast includes ...
Its registered office is located in Waregem, Belgium, [citation needed] and its headquarters is located at Rotterdam, Netherlands. [2] Founded as Arseus NV , it was formerly the Professional Health Division of Omega Pharma , and became an independent entity via an IPO on October 5, 2007 and has been listed on Euronext Brussels and Euronext ...
For premium support please call: 800-290-4726 more ways to reach us
UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium.UCB is an international company with revenue of €4.178 billion in 2016 [2] which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. [2]
BTG Limited is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The current name was adopted when the British Technology Group changed its name on 27 May 1998. [2]